The potential of 211Astatine for NIS-mediated radionuclide therapy in prostate cancer.

MLA

Willhauck, Michael J., et al. “The Potential of 211Astatine for NIS-Mediated Radionuclide Therapy in Prostate Cancer.” European Journal of Nuclear Medicine and Molecular Imaging, vol. 35, no. 7, July 2008, pp. 1272–81. EBSCOhost, https://doi.org/10.1007/s00259-008-0775-4.

APA

Willhauck, M. J., Samani, B.-R. S., Wolf, I., Senekowitsch-Schmidtke, R., Stark, H.-J., Meyer, G. J., Knapp, W. H., Göke, B., Morris, J. C., & Spitzweg, C. (2008). The potential of 211Astatine for NIS-mediated radionuclide therapy in prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 35(7), 1272–1281. https://doi.org/10.1007/s00259-008-0775-4

Chicago

Willhauck, Michael J, Bibi-Rana Sharif Samani, Ingo Wolf, Reingard Senekowitsch-Schmidtke, Hans-Jürgen Stark, Geerd J Meyer, Wolfram H Knapp, Burkhard Göke, John C Morris, and Christine Spitzweg. 2008. “The Potential of 211Astatine for NIS-Mediated Radionuclide Therapy in Prostate Cancer.” European Journal of Nuclear Medicine and Molecular Imaging 35 (7): 1272–81. doi:10.1007/s00259-008-0775-4.